Magazine Article | April 1, 2016

Takeda CEO Mandate Sets Off A Nano Reaction

Source: Life Science Leader

By Louis Garguilo, Chief Editor, Outsourced Pharma
Follow Me On Twitter @Louis_Garguilo

When recently promoted Takeda CEO Christophe Weber announced in the spring of 2015 that his company was determined to become a global leader in gastroenterology (GI), John Puisis, just a few miles from Takeda’s offices in Deerfield, IL, straightened up in his chair. As CEO of Cour Pharmaceutical Development Company, Inc., Puisis had already entered discussions with some pharma companies about Cour’s nanotechnology platform aimed at a GI-related disease.